BioSpace News Archive

Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today provided guidance on their work to develop a peptide vaccine against the new coronavirus SARS-CoV-2 using the company’s proprietary and patented Ii-Key immune system activation technology.

Abbott will announce its first-quarter 2020 financial results on Thursday, April 16, 2020, before the market opens.

OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced an update on shareholder proxy voting in relation to the business combination with Curetis.

Dragonfly Therapeutics, Inc. (“Dragonfly”), today announced an expansion of its strategic collaboration with Merck, known as MSD outside the United States and Canada to discover, develop and commercialize a number of Dragonfly’s candidate natural killer (“NK”) cell engager immunotherapies for oncology, infectious disease, and immune disorders.

Dragonfly Therapeutics, Inc. (“Dragonfly” or the “Company”) today announced that Fidelity Management & Research Company (“Fidelity”) has led a new round of investment in Dragonfly, along with other major investors.

Foundation also allows current grantees flexibility to help those affected by the coronavirus

Coronavirus DNA Health Report Uses Individuals’ Genetic Data to Evaluate Risks and Provide Detailed Guidance on Lifestyle Changes to Lower Infection Risks

The Deputy Prime Minister will chair the Cabinet Committee on the federal response to the coronavirus disease (COVID-19).

ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) recently filed for patent protection for new applications of its AAGP® molecu

Following the successful early-stage validation of Cyclica’s Ligand Express® platform from an initial collaboration, NeuroTheryX Canada Ltd. (NeuroTheryX) and Cyclica, Inc. (Cyclica) form a new joint venture, NineteenGale Therapeutics (NineteenGale) to identify and develop novel cannabinoid-inspired drugs for bipolar disorder, anxiety, and pain management.